Botanix Pharmaceuticals Limited (BXPHF)
OTC
Healthcare
Medical - Pharmaceuticals
$0.01
▲ +0.00%
Market Cap
$25.9M
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Beta
0.86
52-Wk Range
0.0114-0.1413
CEO
Howie McKibbon
Country
AU
Currency
USD
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the treatment of papulopustular rosacea; and BTX 1204A …
Open full interactive analysis & DCF →